The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances ...

LifeRx.md announced that it has implemented reduced pricing for its personalized GLP-1 and GIP treatment programs, a development the organization states is intended to align with the federal ...

According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...

VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent ...

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the ...

"All of this stuff just scares the crap out of me." The post People Jabbing Themselves With Black Market “GLP-3” Drugs ...

PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) ...

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...

Researchers believe they may have the next, better version of Ozempic in the works. At Tufts University, scientists have developed a new drug that aims to boost weight loss while also reducing the ...